BETHESDA, Md--Planning for science is "oxymoronic,"
because you can't plan for results, NCI Director Richard Klausner
told the National Cancer Advisory Board (NCAB). "Instead,
you have to plan for facilitating large-scale thinking,"
The NCI will try to do just that by establishing an environment
in which science can take place. "The NCI Office of Science
Policy, headed by Dr. Edward H. Harlow, will be our nerve center
for science planning," Dr. Klausner said. "Dr. Harlow
will be working over the next year on strategic planning and the
formation of new working groups to get us where we need to go."
In his report on the NCI's budget proposal for the 1997/98 fiscal
year, Dr. Klausner presented the board with an 80-page booklet,
The Nation's Investment in Cancer Research, which gives
the proposed bypass budget as well as a history of NCI's progress
against cancer and an explanation of NCI's research programs,
infrastructure, and opportunities for new investments.
"This booklet is designed to give the President, the Congress,
and the people of the United States a glimpse of NCI, who we are,
what we are, and how money is handled," he said. [The booklet
may be ordered by calling 1-800-4-CANCER (1-800-422-6237).]
Dr. Klausner also explained the steps NCI's intramural program
is taking to develop a vaccine against human papil-lomavirus (HPV),
which has been identified as the cause of most cases of cervical
Investigators have found a way to use certain insect cells that
produce a high quantity of very immunogenic viral particles, he
said. These particles are being used to introduce excellent immune
responses to HPV-16, the form of HPV that accounts for about 50%
of all HPV infections.
"We will be jumping on this discovery as an immediate opportunity
to push through a program for the development of an effective
human vaccine for HPV that will act as a systemic means of protection,"
he said. The researchers plan to come up with a mix that will
give people coverage for about 80% of all HPV types.